Oxford Immunotec Global PLC (NASDAQ: OXFD) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitabiliy, dividends, valuation and analyst recommendations.

Insider & Institutional Ownership

87.5% of Oxford Immunotec Global PLC shares are owned by institutional investors. 7.6% of Oxford Immunotec Global PLC shares are owned by insiders. Comparatively, 6.2% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Oxford Immunotec Global PLC and Myriad Genetics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Immunotec Global PLC 0 0 2 0 3.00
Myriad Genetics 3 8 1 0 1.83

Oxford Immunotec Global PLC presently has a consensus price target of $19.00, indicating a potential upside of 23.86%. Myriad Genetics has a consensus price target of $21.82, indicating a potential downside of 16.90%. Given Oxford Immunotec Global PLC’s stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Immunotec Global PLC is more favorable than Myriad Genetics.

Valuation and Earnings

This table compares Oxford Immunotec Global PLC and Myriad Genetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Oxford Immunotec Global PLC $90.47 million 3.89 -$22.95 million ($1.05) -14.61
Myriad Genetics $757.30 million 2.36 $122.60 million $0.45 58.35

Myriad Genetics has higher revenue and earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.


This table compares Oxford Immunotec Global PLC and Myriad Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oxford Immunotec Global PLC -25.83% -31.48% -22.01%
Myriad Genetics 4.26% 10.53% 6.64%

Volatility and Risk

Oxford Immunotec Global PLC has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.


Myriad Genetics beats Oxford Immunotec Global PLC on 7 of the 13 factors compared between the two stocks.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

Myriad Genetics Company Profile

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.